BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

QURE upcoming catalysts

UniQure Biopharma B.V.: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 1 upcoming FDA decision event(s), and in the last 12 months 0 readout(s) and 0 FDA event(s). Subscribe to QURE (.ics).

Drugs: AAV9-hSyn1-miGRIK2

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
2027-05-01PDUFA date (company-disclosed)pendinguniQure N.V. QUREifezuntirgenePDUFA May 1, 2027 - uniQure N.V. (ifezuntirgene)

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P1/P2UniQure Biopharma B.V. QURENCT06063850 AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe EpilepsyMesial Temporal Lobe Epilepsyrecruiting12

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No readouts in the last 12 months.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.